志賀桿菌檢測套組市場 - 全球產業規模、佔有率、趨勢、機會及預測（按檢測類型、技術、最終用戶、地區和競爭格局分類，2021-2031年）

全球志賀氏菌檢測套組市場預計將從 2025 年的 1.7886 億美元成長到 2031 年的 2.7008 億美元，複合年成長率為 7.11%。

這些試劑盒是用於識別臨床糞便檢體中志賀氏菌抗原或遺傳物質的重要診斷設備，利用側向層析免疫檢測和分子聚合酵素鏈鎖反應等技術來確診志志賀氏桿菌感染。市場成長的主要驅動力是全球食源性疾病發生率的不斷上升，以及檢測抗藥性菌株的迫切需求，而準確的藥敏試驗對於指導有效治療至關重要。英國健康與安全執行局的數據顯示，預計到2023年，廣泛抗藥性志志賀桿菌菌病例將激增53%，凸顯了快速、精準的診斷能力對於應對這一日益嚴重的公共衛生威脅的緊迫性。

儘管成長要素強勁，但先進分子診斷平台的高昂實施成本仍是該市場面臨的一大障礙。這個經濟門檻限制了資源匱乏地區（通常是痢疾高發地區）採用現代檢測方案。此外，這些發展中地區檢查室基礎設施不足，也使得全面檢測通訊協定的實施更加複雜，阻礙了該市場在全球範圍內的推廣和擴張。

市場促進因素

多重抗藥性志志賀桿菌菌株的日益增多是全球志賀桿菌檢測套組市場的主要促進因素。對阿奇黴素和Ciprofloxacin等第一線標準抗生素的抗藥性不斷增強，使得臨床檢查室迫切需要部署先進的診斷解決方案，以識別病原體及其特定的抗藥性標記，從而確保有效治療。近期關於危險突變菌株傳播的監測數據凸顯了這種迫切性。 2024年8月，加州公共衛生部報告稱，2024年1月至5月期間，該州檢測到的志賀桿菌分離株中，被鑑定為廣泛抗藥性（XDR）菌株的比例上升至12%，較上年的6.8%顯著增加。因此，醫療機構正在優先部署能夠支援準確臨床決策的檢測套組，以應對這些複雜且棘手的感染疾病。

分子診斷技術的進步，使得透過症候群檢測組合實現快速、高通量檢測成為可能，進一步推動了市場成長。從傳統的培養方法轉向多重聚合酵素鏈鎖反應(PCR) 系統，可以同時鑑定志賀氏菌和其他腸道病原體，顯著縮短檢測結果的周轉時間，並增強疫情應對能力。對快速診斷的需求在近期的行業趨勢中顯而易見。 2024 年 3 月，生物梅里埃公司 (bioMérieux) 報告稱，其包含胃腸道檢測在內的非呼吸道 BIOFIRE 檢測組合在 2023 年第四季度的銷售額成長了 20%。美國疾病管制與預防中心 (CDC) 估計，到 2024 年，僅在美國每年就會發生約 45 萬志賀氏桿菌感染，這使得這些先進的診斷工具對於控制巨大的疾病負擔至關重要。

市場挑戰

實施先進分子診斷平台的高成本是全球志賀氏菌檢測套組市場成長的一大障礙。這一經濟障礙嚴重限制了資源匱乏經濟體（疾病負擔最重的地區）採用現代檢測方案。這些發展中地區的醫療預算往往捉襟見肘，導致醫療機構無力購買和維護進行精準藥敏分析所需的昂貴設備。因此，該市場面臨結構性擴張限制，未能充分滿足臨床需求最迫切地區的市場需求。

這些地區檢測基礎設施的匱乏進一步加劇了必要檢測通訊協定實施的困難。無法建立可靠的診斷能力阻礙了複雜抗藥性菌株的識別，最終限制了市場潛力。近期抗藥性的趨勢凸顯了這個問題的嚴重性，而這需要先進的檢測技術。根據加州公共衛生部統計，2024年1月至5月，廣泛抗藥性的志志賀桿菌分離株的盛行率上升至12%，比前一年增加了78%。抗藥性的激增凸顯了對先進診斷技術的迫切需求，然而，這些工具的高昂成本仍然阻礙著市場滲透和整個產業的成長。

市場趨勢

多症候群胃腸道病原體檢測組合的廣泛應用正在改變市場格局，解決了臨床上區分志志賀氏桿菌感染與其他症狀相似的腸道病原體感染疾病的難題。與傳統的單一標靶檢測不同，這些綜合檢測組合能夠同時檢測多種細菌、病毒和寄生蟲，從而降低診斷的不確定性，並在複雜的臨床情況下最佳化患者管理。這種提高診斷準確性的趨勢在近期推出的產品中也得到了體現。例如，凱傑公司宣布將於2024年6月在美國推出QIAstat-Dx胃腸道病原體檢測組合2，該組合可在約一小時內快速識別多達16種常見的胃腸道病原體。

同時，隨著醫療機構尋求簡化高通量診斷流程並緩解長期存在的人員短缺問題，自動化即時PCR檢測在臨床檢查室中的應用正在加速推進。醫療機構擴大採用全自動分子平台，這些平台能夠最大限度地減少人工操作並提高檢測通量，從而實現常規胃腸道檢體的高效處理，突破了人工方法的局限性。這種向自動化營運的轉變顯著推動了商業性應用，Seegene公司報告稱，其胃腸道診斷產品在2024年5月的銷售額同比成長了36%。這項業績主要得益於成功拓展了向先進自動化解決方案轉型的新客戶。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球志志賀桿菌檢測套組市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依檢測類型（橫向流動化驗、酵素免疫分析法(ELISA)、聚合酵素鏈鎖反應(PCR) 檢測、其他）
  • 依技術分類（傳統診斷檢驗、核酸檢驗、其他）
  • 依最終使用者（醫院、診斷檢查室、研究機構等）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美志志賀桿菌檢測套組市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲志賀桿菌檢測套組市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區志賀桿菌檢測套組市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東與非洲志賀桿菌檢測套組市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美志志賀桿菌檢測套組市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球志賀桿菌檢測套組市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• Meridian Bioscience, Inc.
• QIAGEN NV
• Diasorin SpA
• Bio-Rad Laboratories Inc.
• BioMerieux SA
• Hygiena LLC
• Molbio Diagnostics Pvt. Ltd.
• Fujirebio Diagnostics, Inc.
• CTK Biotech, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Shigella Test Kit Market is projected to expand from USD 178.86 Million in 2025 to USD 270.08 Million by 2031, reflecting a CAGR of 7.11%. These kits serve as essential diagnostic instruments for identifying Shigella antigens or genetic material in clinical stool specimens, utilizing technologies such as lateral flow immunoassays and molecular polymerase chain reaction to confirm shigellosis infections. The market is primarily propelled by the increasing global incidence of foodborne diseases and the critical requirement to detect antimicrobial-resistant strains, which necessitate accurate sensitivity profiling to direct effective treatment. Data from the UK Health Security Agency indicates that extensively antibiotic-resistant Shigella cases surged by 53 percent in 2023, highlighting the urgent need for rapid and precise diagnostic capabilities to address this growing public health threat.

Despite these strong growth factors, the market encounters a significant obstacle regarding the high implementation expenses of advanced molecular diagnostic platforms. This financial hurdle restricts the adoption of modern testing solutions in resource-limited settings, which are often the regions where shigellosis is most endemic. Furthermore, the lack of adequate laboratory infrastructure in these developing areas complicates the application of comprehensive testing protocols, thereby hindering the market's global reach and expansion.

Market Driver

The escalating burden of multidrug-resistant Shigella strains acts as a primary catalyst for the Global Shigella Test Kit Market. As resistance to standard first-line antibiotics like azithromycin and ciprofloxacin intensifies, clinical laboratories are urged to implement advanced diagnostic solutions capable of identifying both the pathogen and specific resistance markers to ensure effective therapy. This urgency is emphasized by recent surveillance data on the spread of dangerous variants; the California Department of Public Health reported in August 2024 that the percentage of Shigella isolates identified as extensively drug-resistant (XDR) in California increased to 12% between January and May 2024, a significant rise from 6.8% the previous year. Consequently, healthcare providers are prioritizing test kits that support accurate clinical decision-making to manage these complex, hard-to-treat infections.

Technological progress in molecular diagnostics further drives market growth by facilitating rapid, high-throughput detection via syndromic testing panels. The transition from traditional culture methods to multiplex polymerase chain reaction (PCR) systems enables the simultaneous identification of Shigella and other enteric pathogens, significantly reducing turnaround times and enhancing outbreak response. This demand for rapid diagnostics is evident in recent industry performance; BioMerieux reported in March 2024 that sales for its BIOFIRE non-respiratory panels, which include gastrointestinal testing, grew by 20% in the fourth quarter of 2023. These advanced tools are vital for managing the substantial disease burden, as the Centers for Disease Control and Prevention estimated in 2024 that approximately 450,000 Shigella infections occur annually in the United States alone.

Market Challenge

The substantial implementation costs associated with advanced molecular diagnostic platforms present a major impediment to the growth of the Global Shigella Test Kit Market. This financial barrier severely limits the adoption of modern testing solutions in resource-limited economies, which represent the regions with the highest endemic burden of the disease. Since healthcare budgets in these developing areas are often restricted, facilities are unable to procure or maintain the expensive instrumentation required for precise sensitivity profiling. Consequently, the market faces a structural ceiling on its expansion, remaining unable to capitalize on the demand in geographies where the clinical need is most acute.

The insufficiency of laboratory infrastructure in these regions further complicates the deployment of necessary testing protocols. This inability to establish robust diagnostic frameworks prevents the identification of complex resistant strains, thereby limiting the market's reach. The severity of this issue is underscored by recent resistance trends that require such advanced detection; according to the California Department of Public Health, in 2024, the prevalence of extensively drug-resistant Shigella isolates rose to 12 percent between January and May, reflecting a 78 percent increase compared to the previous year. This escalation in resistance highlights the critical need for advanced diagnostics, yet the prohibitive costs associated with these tools continue to hamper their market penetration and overall industry growth.

Market Trends

The widespread adoption of multiplex syndromic gastrointestinal panels is transforming the market by addressing the clinical difficulty of distinguishing shigellosis from infections caused by other enteric pathogens with identical symptom profiles. Unlike traditional single-target tests, these comprehensive panels allow for the simultaneous detection of a wide array of bacteria, viruses, and parasites, thereby reducing diagnostic uncertainty and optimizing patient management in complex clinical scenarios. This trend toward broader diagnostic granularity is illustrated by recent product launches; for instance, Qiagen announced in June 2024 the U.S. launch of its QIAstat-Dx Gastrointestinal Panel 2, which enables the rapid identification of up to 16 common gastrointestinal pathogens in approximately one hour.

Simultaneously, the integration of automated real-time PCR assays in clinical laboratories is accelerating as facilities seek to streamline high-volume diagnostic workflows and alleviate chronic staff shortages. Healthcare providers are increasingly adopting fully automated molecular platforms that minimize manual handling and enhance throughput, allowing for the efficient processing of routine gastrointestinal samples beyond the capacity of manual methods. This operational shift toward automation is driving significant commercial uptake; Seegene Inc. reported in May 2024 that sales for its gastrointestinal diagnostic products grew by 36 percent year-over-year, a performance attributed to the successful acquisition of new customers transitioning to advanced automated solutions.

Key Market Players

• Thermo Fisher Scientific Inc.
• Meridian Bioscience, Inc.
• QIAGEN N.V.
• Diasorin S.p.A.
• Bio-Rad Laboratories Inc.
• BioMerieux SA
• Hygiena LLC
• Molbio Diagnostics Pvt. Ltd.
• Fujirebio Diagnostics, Inc.
• CTK Biotech, Inc.

Report Scope

In this report, the Global Shigella Test Kit Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Shigella Test Kit Market, By Test Type

• Lateral flow assays
• Enzyme-linked immunosorbent assay (ELISA)
• Polymerase chain reaction (PCR) assay
• Others

Shigella Test Kit Market, By Technology

• Conventional diagnostic tests
• Nucleic acid-based tests
• Others

Shigella Test Kit Market, By End User

• Hospitals
• Diagnostic laboratories
• Research institutes
• Others

Shigella Test Kit Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Shigella Test Kit Market.

Available Customizations:

Global Shigella Test Kit Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Shigella Test Kit Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Lateral flow assays, Enzyme-linked immunosorbent assay (ELISA), Polymerase chain reaction (PCR) assay, Others)
  • 5.2.2. By Technology (Conventional diagnostic tests, Nucleic acid-based tests, Others)
  • 5.2.3. By End User (Hospitals, Diagnostic laboratories, Research institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Shigella Test Kit Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Technology
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Shigella Test Kit Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Shigella Test Kit Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Shigella Test Kit Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By End User

7. Europe Shigella Test Kit Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Technology
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Shigella Test Kit Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By End User
  • 7.3.2. France Shigella Test Kit Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Shigella Test Kit Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Shigella Test Kit Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Shigella Test Kit Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By End User

8. Asia Pacific Shigella Test Kit Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Technology
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Shigella Test Kit Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By End User
  • 8.3.2. India Shigella Test Kit Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Shigella Test Kit Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Shigella Test Kit Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Shigella Test Kit Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By End User

9. Middle East & Africa Shigella Test Kit Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Technology
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Shigella Test Kit Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Shigella Test Kit Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Shigella Test Kit Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By End User

10. South America Shigella Test Kit Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Technology
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Shigella Test Kit Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Shigella Test Kit Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Shigella Test Kit Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Shigella Test Kit Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Meridian Bioscience, Inc.
• 15.3. QIAGEN N.V.
• 15.4. Diasorin S.p.A.
• 15.5. Bio-Rad Laboratories Inc.
• 15.6. BioMerieux SA
• 15.7. Hygiena LLC
• 15.8. Molbio Diagnostics Pvt. Ltd.
• 15.9. Fujirebio Diagnostics, Inc.
• 15.10. CTK Biotech, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer